Gabrielle M. Grasso on Muck Rack

Gabrielle M. Grasso

Verified
New Jersey
As seen in: Healio, Healio Dermatology, Flipboard, Endocrine Today, Healio Gastroenterology, Healio Ophthalmology, Nephrology News & Issues, Orthopedics Today, Annals of Family Medicine, Citeline, New Jersey Digest
I believe in absolute truth and little to no room for interpretation of the United States Constitution. Ideas my own💡 jokes mine unless u don’t find them funny
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gabrielle

Contact Gabrielle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Estrogen therapy for menopausal hair loss lacks sufficient scientific support

|
By Gabrielle M. Grasso Verified
| Healio Dermatology Verified
Key takeaways: In a review of 13 studies, researchers did not find sufficient evidence supporting the use of estrogen therapy for menopausal hair loss. Both topical and systemic estrogen therapy posed safety concerns as well. Topical estrogen and systemic menopausal hormone therapy did not improve hair growth for women going through menopause, according to a systematic review published in the Journal of the American Academy of Dermatology.
Open in Who Shared Issue with article?

‘Room to do better’: Nearly 1 in 3 people with vitiligo do not receive treatment Original

|
By Gabrielle M. Grasso Verified
| Healio Dermatology Verified
‘Room to do better’: Nearly 1 in 3 people with vitiligo do not receive treatment Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Open in Who Shared View Duplicates (2) Issue with article?

‘High long-term efficacy’ with sonelokimab for hidradenitis suppurativa: Topline data

|
By Gabrielle M. Grasso Verified
| Healio Dermatology Verified
Key takeaways: More than 33% of adults who received sonelokimab achieved complete HS clearance with no increase in draining tunnels by 1 year. New interim data showed teens had a greater response rate than adults. Adults who received sonelokimab for moderate to severe hidradenitis suppurativa experienced consistent disease improvement through 1 year, according to topline data.
Open in Who Shared Issue with article?
See all 1,030 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified